Adoptive transfer of MAGE-A4 T-cell receptor gene-transduced lymphocytes in patients with recurrent esophageal cancer

Clinical Cancer Research

Volumn 21, Issue 10, 2015, Pages 2268-2277

  Kageyama, Shinichi ^a   Ikeda, Hiroaki ^a   Miyahara, Yoshihiro ^a   Imai, Naoko ^a   Ishihara, Mikiya ^b   Saito, Kanako ^a   Sugino, Sahoko ^a   Ueda, Shugo ^c   Ishikawa, Takeshi ^d   Kokura, Satoshi ^d   Naota, Hiroaki ^e   Ohishi, Kohshi ^b   Shiraishi, Taizo ^a   Inoue, Naoki ^f   Tanabe, Masashige ^f   Kidokoro, Tomohide ^f   Yoshioka, Hirofumi ^f   Tomura, Daisuke ^f   Nukaya, Ikuei ^f   Mineno, Junichi ^f   Takesako, Kazutoh ^f   Katayama, Naoyuki ^a   Shiku, Hiroshi ^a   more..

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b MIE UNIVERSITY HOSPITAL   (Japan)

^c Kitano Hospital   (Japan)

^d KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^e Matsusaka Chuo Hospital   (Japan)

^f TAKARA BIO INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MELANOMA ANTIGEN 4; T LYMPHOCYTE RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR; MAGEA4 PROTEIN, HUMAN; TUMOR ANTIGEN; TUMOR PROTEIN;

ADOPTIVE TRANSFER; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CELL INFILTRATION; CELL SURVIVAL; CELL THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG CROSS REACTIVITY; DRUG DOSE ESCALATION; DRUG SAFETY; ESOPHAGUS CANCER; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; IN VIVO STUDY; INJECTION SITE INDURATION; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN REDNESS; T LYMPHOCYTE; TCR GENE; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; CARCINOMA, SQUAMOUS CELL; CELL CULTURE; CLINICAL TRIAL; ESOPHAGEAL NEOPLASMS; GENETIC TRANSDUCTION; GENETICS; IMMUNOLOGY; MIDDLE AGED; TRANSPLANTATION; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADOPTIVE TRANSFER; ADULT; AGED; ANTIGENS, NEOPLASM; CARCINOMA, SQUAMOUS CELL; CELL SURVIVAL; CELLS, CULTURED; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES; TRANSDUCTION, GENETIC; TREATMENT OUTCOME;

EID: 84933185539     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-1559     Document Type: Article

References (41)

1. Dudley ME, Wunderlich J, Nishimura MI, Yu D, Yang JC, Topalian SL, et al. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother 2001;24:363-73.
2. Yee C, Thompson JA, Byrd D, Riddell SR, Roche P, Celis E, et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A 2002; 99:16168-73.
3. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005;23:2346-57.
4. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008;26:5233-9.
5. Robbins PF, Dudley ME, Wunderlich J, El-Gamil M, Li YF, Zhou J, et al. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol 2004;173:7125-30.
6. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006;314:126-9.
7. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 2011;29:917-24.
8. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011;365: 725-33.
9. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011;3: 95ra73.
10. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013;368:1509-18.
11. Brentjens RJ, Riviere I, Park JH, Davila ML, Wang X, Stefanski J, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011;118:4817-28.
12. Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012;119: 2709-20.
13. Miyahara Y, Naota H, Wang L, Hiasa A, Goto M, Watanabe M, et al. Determination of cellularly processed HLA-A2402-restricted novel CTL epitopes derived from two cancer germ line genes, MAGE-A4 and SAGE. Clin Cancer Res 2005;11:5581-9.
14. Hiasa A, Hirayama M, Nishikawa H, Kitano S, Nukaya I, Yu SS, et al. Longterm phenotypic, functional and genetic stability of cancer-specific T-cell receptor (TCR) alphabeta genes transduced to CD8+ T cells. Gene Ther 2008;15:695-9.
15. Haier J, Owzcareck M, Guller U, Spagnoli GC, Burger H, Senninger N, et al. Expression of MAGE-A cancer/testis antigens in esophageal squamous cell carcinomas. Anticancer Res 2006;26:2281-7.
16. Akcakanat A, Kanda T, Tanabe T, Komukai S, Yajima K, Nakagawa S, et al. Heterogeneous expression of GAGE, NY-ESO-1, MAGE-A and SSX proteins in esophageal cancer: Implications for immunotherapy. Int J Cancer 2006;118:123-8.
17. Imai N, Ikeda H, Tawara I, Shiku H. Tumor progression inhibits the induction of multifunctionality in adoptively transferred tumor-specific CD8+ T cells. Eur J Immunol 2009;39:241-53.
18. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003;13:176-81.
19. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
20. Yoshida N, Abe H, Ohkuri T, Wakita D, Sato M, Noguchi D, et al. Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens and Tcell infiltration in non-small cell lung carcinoma and their prognostic significance. Int J Oncol 2006;28:1089-98.
21. Kocher T, Schultz-Thater E, Gudat F, Schaefer C, Casorati G, Juretic A, et al. Identification and intracellular location of MAGE-3 gene product. Cancer Res 1995;55:2236-9.
22. Soga N, Hori Y, Yamakado K, Ikeda H, Imai N, Kageyama S, et al. Limited expression of cancer-testis antigens in renal cell carcinoma patients. Mol Clin Oncol 2013;1:326-30.
23. Landry C, Brasseur F, Spagnoli GC, Marbaix E, Boon T, Coulie P, et al. Monoclonal antibody 57B stains tumor tissues that express gene MAGE-A4. Int J Cancer 2000;86:835-41.
24. Dorner BG, Scheffold A, Rolph MS, Huser MB, Kaufmann SHE, Radbruch A, et al. A MIP-1a, MIP-1b, RANTES, and ATAC/lymphotactin function together with IFN-g as type 1 cytokines. Proc Natl Acad Sci U S A 2002;99:6181-6.
25. Sallusto F, Lenig D, Foerster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999;401:708-12.
26. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effectormemory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 2004;22:745-63.
27. Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009;114:535-46.
28. Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G, et al. Virus-specific T cells engineeredto coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 2008;14:1264-70.
29. Gattinoni L, Powell DJ Jr, Rosenberg SA, Restifo NP. Adoptive immu-notherapy for cancer: building on success. Nat Rev Immunol 2006; 6:383-93.
30. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 2012;12:269-81.
31. Ohigashi Y, Sho M, Yamada Y, Tsurui Y, Hamada K, Ikeda N, et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res 2005;11:2947-53.
32. Gao J, Wu Y, Su Z, Barnie PA, Jiao Z, Qingli B, et al. Infiltration of alternatively activated macrophages in cancer tissue is associated with MDSC and Th2 polarization in patients with esophageal cancer. PLoS ONE 2014;9:e104453.
33. Muro K, Hamaguchi T, Ohtsu A, Boku N, Chin K, Hyodo I, et al. A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol 2004;15:955-9.
34. Tew WP, Kelsen DP, Ilson DH. Targeted therapies for esophageal cancer. Oncologist 2005;10:590-601.
35. Shirakura Y, Mizuno Y, Wang L, Imai N, Amaike C, Sato E, et al. T-cell receptor gene therapy targeting melanoma-associated antigen-A4 inhibits human tumor growth in non-obese diabetic/SCID/gcnull mice. Cancer Sci 2012;103:17-25.
36. Muraoka D, Kato T, Wang L, Maeda Y, Noguchi T, Harada N, et al. Peptide vaccine induces enhanced tumor growth associated with apoptosis induction in CD8+ T Cells. J Immunol 2010;185:3768-76.
37. Hailemichael Y, Dai Z, Jaffarzad N, Ye Y, Medina MA, Huang XF, et al. Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion. Nat Med 2013;19:465-72.
38. Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan DA, Feldman SA, et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther 2011;19:620-6.
39. Linette GP, Stadtmauer EA, Maus MV, Rapoport AP, Levine BL, Emery L, et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 2013;122:863-71.
40. Cameron BJ, Gerry AB, Dukes J, Harper JV, Kannan V, Bianchi FC, et al. Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci Transl 2013;197ra103.
41. Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, Zheng Z, et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother 2013;36:133-51.